Tune Therapeutics

Durham, United States

Tune Therapeutics is an epigenetic programming platform for the treatment of disease.

$175.0M raised

Jan 2025

Series B

Biotechnology Health Care Therapeutics

Top Investors

New Enterprise AssociatesHatteras Venture PartnersMission BioCapitalYosemiteEmerson Collective

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Tune Therapeutics

How much funding has Tune Therapeutics raised?

Tune Therapeutics has raised $175.0M in total funding. The most recent round was Series B. The last funding was announced in January 2025.

Who are Tune Therapeutics's investors?

Tune Therapeutics's investors include New Enterprise Associates, Hatteras Venture Partners, Mission BioCapital, Yosemite, Emerson Collective.

Where is Tune Therapeutics headquartered?

Tune Therapeutics is headquartered in Durham, United States.

What does Tune Therapeutics do?

Tune Therapeutics is an epigenetic programming platform for the treatment of disease.

What stage is Tune Therapeutics at?

Tune Therapeutics is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 12, 2025.

MLA

"Tune Therapeutics — Funding & Investors." VCBacked, January 12, 2025, https://www.vcbacked.co/company/tune-therapeutics. Accessed June 4, 2026.

APA

VCBacked. (2025). Tune Therapeutics — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/tune-therapeutics

Wikipedia (cite web)

{{cite web |title=Tune Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tune-therapeutics |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 12, 2025.

Similar Companies in Biotechnology